Compositions and methods for treating lymphoma
View Patent ↗This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.
1. A method of treating a relapsed cancer in a human, said method comprising coadministering to said human a pharmaceutical composition comprising liposome-encapsulated vincristine with Rituximab, wherein said relapsed cancer is a lymphoma or leukemia, and wherein said human has previously undergone at least one multi-agent combination regime.
2. The method of claim 1 , wherein said liposome comprises sphingomyelin and cholesterol.
3. The method of claim 2 , wherein the ratio of sphingomyelin to cholesterol is between 75/25 (mol % sphingomyelin/mol % cholesterol) and 50/50 (mol % sphingomyelin/mol % cholesterol).
4. The method of claim 3 , wherein the ratio of sphingomyelin to cholesterol is 55/45 (mol % sphingomyelin/mol % cholesterol).
5. The method of claim 1 , wherein said vincristine is administered at a dosage of between 1.4–2.4 mg/m 2 .
6. The method of claim 1 , wherein said lymphoma is non-Hodgkin's lymphoma.
7. A method of treating a relapsed cancer in a human, said method comprising coadministering to said human a pharmaceutical composition comprising liposome-encapsulated vincristine with iodine 131 (131I) Lym-1, wherein said relapsed cancer is a lymphoma or leukemia, and wherein said human has previously undergone at least one multi-agent combination regime.
8. The method of claim 7 , wherein said liposome comprises sphingomyelin and cholesterol.
9. The method of claim 8 , wherein the ratio of sphingomyelin to cholesterol is between 75/25 (mol % sphingomyelin/mol % cholesterol) and 50/50 (mol % sphingomyelin/mol % cholesterol).
10. The method of claim 7 , wherein said lymphoma is non-Hodgkin's lymphoma.
11. A method of treating a relapsed cancer in a human, said method comprising coadministering to said human a pharmaceutical composition comprising liposome-encapsulated vincristine with iodine 131 (131I) tositumomab, wherein said relapsed cancer is a lymphoma or leukemia, and wherein said human has previously undergone at least one multi-agent combination regime.
12. The method of claim 11 , wherein said liposome comprises sphingomyelin and cholesterol.
13. The method of claim 12 , wherein the ratio of sphingomyelin to cholesterol is between 75/25 (mol % sphingomyelin/mol % cholesterol) and 50/50 (mol % sphingomyelin/mol % cholesterol).
14. The method of claim 11 , wherein said lymphoma is non-Hodgkin's lymphoma.